{"id":76605,"date":"2026-05-05T12:27:13","date_gmt":"2026-05-05T06:57:13","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=76605"},"modified":"2026-05-05T12:27:15","modified_gmt":"2026-05-05T06:57:15","slug":"marksans-pharma-q4-results-2026-preview","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/","title":{"rendered":"Marksans Pharma Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"},"content":{"rendered":"<p>Marksans Pharma (MARKSANS) Q4 results for FY26 are expected in May 2026. With Q3 FY26 revenue of Rs 602 Cr and PAT of Rs 92 Cr as the base, the street is watching closely for margin trajectory and management guidance on FY27 demand.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Get Free SEBI-Registered Research on Marksans Pharma \u00e2\u20ac\u201d Click Here<\/strong><\/a><\/p>\n<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Marksans_Pharma_Q4_FY26_Earnings_Preview_aE%E2%80%9D_What_to_Expect\" title=\"Marksans Pharma Q4 FY26 Earnings Preview \u00e2\u20ac\u201d What to Expect\">Marksans Pharma Q4 FY26 Earnings Preview \u00e2\u20ac\u201d What to Expect<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Marksans_Pharma_Q4_Results_2026_aE%E2%80%9D_Date_and_Key_Estimates\" title=\"Marksans Pharma Q4 Results 2026 \u00e2\u20ac\u201d Date and Key Estimates\">Marksans Pharma Q4 Results 2026 \u00e2\u20ac\u201d Date and Key Estimates<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#5_Reasons_Marksans_Pharma_Q4_Results_Could_Beat_Estimates\" title=\"5 Reasons Marksans Pharma Q4 Results Could Beat Estimates\">5 Reasons Marksans Pharma Q4 Results Could Beat Estimates<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#US_Generics_Business_Recovery\" title=\"US Generics Business Recovery\">US Generics Business Recovery<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Domestic_Formulations_Growth\" title=\"Domestic Formulations Growth\">Domestic Formulations Growth<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#API_Segment_Expansion_via_China_Plus_One\" title=\"API Segment Expansion via China Plus One\">API Segment Expansion via China Plus One<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Complex_Generics_and_Biosimilars_Pipeline\" title=\"Complex Generics and Biosimilars Pipeline\">Complex Generics and Biosimilars Pipeline<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Emerging_Market_Revenue_Diversification\" title=\"Emerging Market Revenue Diversification\">Emerging Market Revenue Diversification<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#5_Key_Risks_to_Watch_in_Marksans_Pharma_Q4_Results\" title=\"5 Key Risks to Watch in Marksans Pharma Q4 Results\">5 Key Risks to Watch in Marksans Pharma Q4 Results<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#USFDA_Inspection_and_Import_Alert_Risk\" title=\"USFDA Inspection and Import Alert Risk\">USFDA Inspection and Import Alert Risk<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#US_Generics_Price_Erosion\" title=\"US Generics Price Erosion\">US Generics Price Erosion<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Raw_Material_Cost_Pressure\" title=\"Raw Material Cost Pressure\">Raw Material Cost Pressure<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#DPCO_Price_Control_Impact\" title=\"DPCO Price Control Impact\">DPCO Price Control Impact<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Currency_Risk_on_Export_Revenues\" title=\"Currency Risk on Export Revenues\">Currency Risk on Export Revenues<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Analyst_Ratings_and_Target_Price_for_Marksans_Pharma\" title=\"Analyst Ratings and Target Price for Marksans Pharma\">Analyst Ratings and Target Price for Marksans Pharma<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Q4_Results_2026_Calendar_aE%E2%80%9D_Key_Dates_to_Track\" title=\"Q4 Results 2026 Calendar \u00e2\u20ac\u201d Key Dates to Track\">Q4 Results 2026 Calendar \u00e2\u20ac\u201d Key Dates to Track<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#How_to_Invest_in_Marksans_Pharma_Based_on_Q4_Results\" title=\"How to Invest in Marksans Pharma Based on Q4 Results\">How to Invest in Marksans Pharma Based on Q4 Results<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Frequently_Asked_Questions_aE%E2%80%9D_Marksans_Pharma_Q4_Results_2026\" title=\"Frequently Asked Questions \u00e2\u20ac\u201d Marksans Pharma Q4 Results 2026\">Frequently Asked Questions \u00e2\u20ac\u201d Marksans Pharma Q4 Results 2026<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-19\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Q_When_will_Marksans_Pharma_announce_Q4_FY26_results\" title=\"Q: When will Marksans Pharma announce Q4 FY26 results?\">Q: When will Marksans Pharma announce Q4 FY26 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-20\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Q_What_is_the_revenue_estimate_for_Marksans_Pharma_Q4_FY26\" title=\"Q: What is the revenue estimate for Marksans Pharma Q4 FY26?\">Q: What is the revenue estimate for Marksans Pharma Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-21\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Q_What_PAT_is_expected_for_Marksans_Pharma_in_Q4_FY26\" title=\"Q: What PAT is expected for Marksans Pharma in Q4 FY26?\">Q: What PAT is expected for Marksans Pharma in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-22\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Q_Will_Marksans_Pharma_declare_a_dividend_in_Q4_FY26\" title=\"Q: Will Marksans Pharma declare a dividend in Q4 FY26?\">Q: Will Marksans Pharma declare a dividend in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-23\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Q_What_is_the_current_share_price_and_market_cap_of_Marksans_Pharma\" title=\"Q: What is the current share price and market cap of Marksans Pharma?\">Q: What is the current share price and market cap of Marksans Pharma?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-24\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Q_What_are_the_key_risks_for_Marksans_Pharma_in_Q4_FY26\" title=\"Q: What are the key risks for Marksans Pharma in Q4 FY26?\">Q: What are the key risks for Marksans Pharma in Q4 FY26?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-25\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Q_Is_Marksans_Pharma_a_buy_before_Q4_results\" title=\"Q: Is Marksans Pharma a buy before Q4 results?\">Q: Is Marksans Pharma a buy before Q4 results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-26\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Q_How_can_I_track_Marksans_Pharma_Q4_results_live\" title=\"Q: How can I track Marksans Pharma Q4 results live?\">Q: How can I track Marksans Pharma Q4 results live?<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-27\" href=\"https:\/\/univest.in\/blogs-2\/marksans-pharma-q4-results-2026-preview\/#Recent_Article\" title=\"Recent Article\">Recent Article<\/a><\/li><\/ul><\/nav><\/div>\n<h2><span class=\"ez-toc-section\" id=\"Marksans_Pharma_Q4_FY26_Earnings_Preview_aE%E2%80%9D_What_to_Expect\"><\/span><strong>Marksans Pharma Q4 FY26 Earnings Preview \u00e2\u20ac\u201d What to Expect<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>The pharma sector is expected to deliver solid Q4 FY26 performance with stabilising US generic pricing, robust domestic formulation growth and a deepening complex generics pipeline supporting both revenue and margin expansion.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Marksans_Pharma_Q4_Results_2026_aE%E2%80%9D_Date_and_Key_Estimates\"><\/span><strong>Marksans Pharma Q4 Results 2026 \u00e2\u20ac\u201d Date and Key Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Parameter<\/th>\n<th>Q3 FY26 Actual<\/th>\n<th>Q4 FY26 Estimate<\/th>\n<th>YoY Growth<\/th>\n<\/tr>\n<tr>\n<td>Revenue (Rs Cr)<\/td>\n<td>602<\/td>\n<td>648<\/td>\n<td>+8%<\/td>\n<\/tr>\n<tr>\n<td>PAT (Rs Cr)<\/td>\n<td>92<\/td>\n<td>105<\/td>\n<td>+14%<\/td>\n<\/tr>\n<tr>\n<td>EBITDA Margin<\/td>\n<td>&#8212;<\/td>\n<td>16.2%<\/td>\n<td>Improvement expected<\/td>\n<\/tr>\n<tr>\n<td>Results Date<\/td>\n<td>&#8212;<\/td>\n<td>May 2026<\/td>\n<td>&#8212;<\/td>\n<\/tr>\n<tr>\n<td>Dividend History<\/td>\n<td colspan=\"3\">Rs 1.00 per share<\/td>\n<\/tr>\n<tr>\n<td>Dividend Expectation<\/td>\n<td colspan=\"3\">Rs 2.00 final dividend expected<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Estimates based on analyst consensus as of April 2026. Actual results may vary. Verify before investing.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Track Marksans Pharma live price, FII\/DII activity and fundamentals on Univest Screener<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"5_Reasons_Marksans_Pharma_Q4_Results_Could_Beat_Estimates\"><\/span><strong>5 Reasons Marksans Pharma Q4 Results Could Beat Estimates<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"US_Generics_Business_Recovery\"><\/span><strong>US Generics Business Recovery<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Pricing erosion in US generics has moderated significantly. New ANDA approvals and first-to-file opportunities in high-value molecules are providing meaningful revenue upside for companies with deep US pipelines.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Domestic_Formulations_Growth\"><\/span><strong>Domestic Formulations Growth<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>India&#8217;s domestic pharma market continues growing at 9 to 11 percent, driven by chronic therapy categories including cardiovascular, diabetes and respiratory, and expanding healthcare access in semi-urban India.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"API_Segment_Expansion_via_China_Plus_One\"><\/span><strong>API Segment Expansion via China Plus One<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>China Plus One sourcing diversification by global pharma companies is creating strong and durable demand for Indian API manufacturers with robust quality regulatory track records.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Complex_Generics_and_Biosimilars_Pipeline\"><\/span><strong>Complex Generics and Biosimilars Pipeline<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Companies investing in complex injectables, biosimilars and specialty drugs are building differentiated pipelines that command significantly higher pricing and margins than standard generics.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Emerging_Market_Revenue_Diversification\"><\/span><strong>Emerging Market Revenue Diversification<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Africa, Latin America and Southeast Asia revenues are growing robustly, providing geographical diversification beyond the US and India and reducing single-market concentration risk.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"5_Key_Risks_to_Watch_in_Marksans_Pharma_Q4_Results\"><\/span><strong>5 Key Risks to Watch in Marksans Pharma Q4 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"USFDA_Inspection_and_Import_Alert_Risk\"><\/span><strong>USFDA Inspection and Import Alert Risk<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>USFDA facility inspections and import alerts remain a persistent overhang; any adverse observation or warning letter can materially disrupt US revenues for multiple quarters.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"US_Generics_Price_Erosion\"><\/span><strong>US Generics Price Erosion<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Competition from Chinese and domestic US manufacturers can re-intensify pricing pressure in base generics molecules, eroding volumes and realisations unexpectedly.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Raw_Material_Cost_Pressure\"><\/span><strong>Raw Material Cost Pressure<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>API and solvent prices, particularly China-sourced intermediates, can spike and compress gross margins sharply if supply disruptions occur.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"DPCO_Price_Control_Impact\"><\/span><strong>DPCO Price Control Impact<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Inclusion of additional drugs in the National List of Essential Medicines limits domestic pricing flexibility and can restrict revenue growth for affected portfolios.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Currency_Risk_on_Export_Revenues\"><\/span><strong>Currency Risk on Export Revenues<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Weakness in export destination currencies against INR reduces international revenue realisation and compresses overseas profitability.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"Analyst_Ratings_and_Target_Price_for_Marksans_Pharma\"><\/span><strong>Analyst Ratings and Target Price for Marksans Pharma<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Brokerage<\/th>\n<th>Rating<\/th>\n<th>Key Thesis<\/th>\n<\/tr>\n<tr>\n<td>Bernstein<\/td>\n<td>Outperform<\/td>\n<td>US generics recovery and complex pipeline launches<\/td>\n<\/tr>\n<tr>\n<td>CLSA<\/td>\n<td>Buy<\/td>\n<td>Domestic growth and API China Plus One opportunity<\/td>\n<\/tr>\n<tr>\n<td>JM Financial<\/td>\n<td>Buy<\/td>\n<td>Margin expansion and emerging market revenue growth<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><em>Analyst ratings are for informational purposes only and subject to change. Not investment advice.<\/em><\/p>\n<p><a href=\"https:\/\/univest.in\/screeners\"><strong>Marksans Pharma share price (MARKSANS) is trading near Rs 278 with a market capitalisation of approximately Rs 8,050 Cr. Track the stock on Univest Screener for live price and fundamental data.<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Q4_Results_2026_Calendar_aE%E2%80%9D_Key_Dates_to_Track\"><\/span><strong>Q4 Results 2026 Calendar \u00e2\u20ac\u201d Key Dates to Track<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<table border=\"1\" cellspacing=\"0\" cellpadding=\"6\">\n<tbody>\n<tr>\n<th>Company<\/th>\n<th>Expected Results Date<\/th>\n<\/tr>\n<tr>\n<td>Marksans Pharma<\/td>\n<td>May 2026<\/td>\n<\/tr>\n<tr>\n<td>TCS<\/td>\n<td>April 2026<\/td>\n<\/tr>\n<tr>\n<td>Infosys<\/td>\n<td>April 2026<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>Stay updated on all Q4 FY26 earnings at <a href=\"https:\/\/univest.in\/blogs\">Univest Blogs<\/a>. For TCS results see <a href=\"https:\/\/univest.in\/blogs\/tcs-q4-results-2026-date-preview\">TCS Q4 Results 2026<\/a> and for Infosys see <a href=\"https:\/\/univest.in\/blogs\/infosys-q4-results-2026-date-preview\">Infosys Q4 Results 2026<\/a>.<\/p>\n<h2><span class=\"ez-toc-section\" id=\"How_to_Invest_in_Marksans_Pharma_Based_on_Q4_Results\"><\/span><strong>How to Invest in Marksans Pharma Based on Q4 Results<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Before investing in Marksans Pharma based on Q4 results, consider the following approach: review the actual revenue and PAT versus analyst estimates, listen to the management earnings call for FY27 guidance, assess whether the EBITDA margin trajectory is improving or deteriorating, and check FII\/DII activity patterns post-results. A beat on estimates with positive guidance is typically a bullish signal; a miss with downgraded guidance may indicate further correction risk.<\/p>\n<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong>Subscribe to Univest Pro for SEBI-registered entry, target and stop-loss levels on Marksans Pharma \u00e2\u20ac\u201d Click Here<\/strong><\/a><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Frequently_Asked_Questions_aE%E2%80%9D_Marksans_Pharma_Q4_Results_2026\"><\/span><strong>Frequently Asked Questions \u00e2\u20ac\u201d Marksans Pharma Q4 Results 2026<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h3><span class=\"ez-toc-section\" id=\"Q_When_will_Marksans_Pharma_announce_Q4_FY26_results\"><\/span><strong>Q: When will Marksans Pharma announce Q4 FY26 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Marksans Pharma (MARKSANS) is expected to announce Q4 FY26 results in May 2026. The exact board meeting date will be communicated via BSE\/NSE exchange filing. Track the date on Univest Screener.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_is_the_revenue_estimate_for_Marksans_Pharma_Q4_FY26\"><\/span><strong>Q: What is the revenue estimate for Marksans Pharma Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Analyst consensus estimates Marksans Pharma Q4 FY26 revenue at approximately Rs 648 Cr, representing approximately 8% year-on-year growth. The actual number will depend on sector demand trends and execution in the quarter.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_PAT_is_expected_for_Marksans_Pharma_in_Q4_FY26\"><\/span><strong>Q: What PAT is expected for Marksans Pharma in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Estimated PAT for Marksans Pharma Q4 FY26 is approximately Rs 105 Cr, up approximately 14% year-on-year. Margin expansion from operating leverage and input cost moderation are the primary drivers of profit growth expectations.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_Will_Marksans_Pharma_declare_a_dividend_in_Q4_FY26\"><\/span><strong>Q: Will Marksans Pharma declare a dividend in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Historical dividend pattern for Marksans Pharma: Rs 1.00 per share. For Q4 FY26, Rs 2.00 final dividend expected. Dividend declarations are subject to board approval at the time of results.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_is_the_current_share_price_and_market_cap_of_Marksans_Pharma\"><\/span><strong>Q: What is the current share price and market cap of Marksans Pharma?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Marksans Pharma (MARKSANS) is currently trading at approximately Rs 278 with a market capitalisation of Rs 8,050 Cr. Track live price, volume and FII\/DII data on <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_What_are_the_key_risks_for_Marksans_Pharma_in_Q4_FY26\"><\/span><strong>Q: What are the key risks for Marksans Pharma in Q4 FY26?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Key risks include: USFDA Inspection and Import Alert Risk, US Generics Price Erosion, Raw Material Cost Pressure. Investors should monitor management commentary on these risks in the Q4 earnings call.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_Is_Marksans_Pharma_a_buy_before_Q4_results\"><\/span><strong>Q: Is Marksans Pharma a buy before Q4 results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>This article does not constitute investment advice. Whether to buy Marksans Pharma before Q4 results depends on your risk appetite, existing portfolio exposure and entry price relative to fair value. Consult a SEBI-registered financial advisor before making any investment decision.<\/p>\n<h3><span class=\"ez-toc-section\" id=\"Q_How_can_I_track_Marksans_Pharma_Q4_results_live\"><\/span><strong>Q: How can I track Marksans Pharma Q4 results live?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n<p>Track Marksans Pharma Q4 FY26 results live on the <a href=\"https:\/\/univest.in\/screeners\">Univest Screener<\/a>, which provides real-time price updates, financial data and analyst research. Download the <a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\">Univest iOS App<\/a> or <a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\">Android App<\/a> for mobile alerts.<\/p>\n<p><em>Disclaimer: Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Consult a SEBI-registered financial advisor before making any investment decisions. SEBI Registration: INH000012449.<\/em><\/p>\n<h2><span class=\"ez-toc-section\" id=\"Recent_Article\"><\/span><strong>Recent Article<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-ahlucont-share-price-falling-key-reasons-2026\">Why Is Ahluwalia Contracts Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-nuvoco-share-price-falling-key-reasons-2026\">Why Is Nuvoco Vistas Corporation Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-capacite-share-price-falling-key-reasons-2026\">Why Is Capacite Infraprojects Share Price Falling Key Reasons 2026<\/a><\/p>\n<p class=\"text-xl font-bold font-Inter mb-4\"><a href=\"https:\/\/univest.in\/blogs\/why-is-psp-projects-share-price-falling-key-reasons-2026\">Why Is PSP Projects Share Price Falling Key Reasons 2026<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Get the complete Marksans Pharma Q4 Results 2026 preview including expected date, revenue estimate of Rs 648 Cr, PAT estimate of Rs 105 Cr and latest analyst ratings. Updated on Univest.<\/p>\n","protected":false},"author":28,"featured_media":81947,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3802,3858,3983],"class_list":["post-76605","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-news","tag-q4-results","tag-q4-results-2026"],"metadata":{"rank_math_internal_links_processed":["1"],"_edit_lock":["1777964272:28"],"_last_editor_used_jetpack":["block-editor"],"rank_math_primary_category":["842"],"rank_math_seo_score":["77"],"rank_math_title":["Marksans Pharma Q4 Results 2026: Date, Revenue, PAT and Analyst Outlook"],"rank_math_description":["Marksans Pharma Q4 Results 2026 preview including expected date, revenue estimate of Rs 648 Cr, PAT estimate of Rs 105 Cr and latest analyst ratings."],"rank_math_focus_keyword":["Marksans Pharma Q4 Results"],"rank_math_robots":["a:2:{i:0;s:8:\"nofollow\";i:1;s:7:\"noindex\";}"],"_wp_old_date":["2026-04-24"],"_thumbnail_id":["81947"],"_edit_last":["28"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["10264"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2026\/04\/05122641\/Marksans-Pharma-Q4-Results-2026.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/76605","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/28"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=76605"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/76605\/revisions"}],"predecessor-version":[{"id":81948,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/76605\/revisions\/81948"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/81947"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=76605"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=76605"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=76605"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}